The use of Low Level Laser Therapy (LLLT) as an alternative and/or as adjunct to conventional medical treatments, has significantly gained acceptance amongst healthcare practitioners in recent years. The technology has proven to add value to practitioners’ businesses and patients are very satisfied with results achieved. It is extensively utilized in Canada, the U.S. and internationally.

Theralase Technologies Inc. (TSXV : TLT & OTC BB : TLTFF) designs, develops and manufactures patented, super-pulsed laser technology used in a wide range of bio-stimulation and bio-destruction clinical applications. The Theralase technology platform targets several diverse healthcare sectors firstly, for non-invasive pain management and clinical therapy, in hundreds of neural muscular skeletal conditions, (including arthritis) secondly, to bio-stimulate and accelerate wound care and healing, (including; bone fracture regeneration and osteoarthritic conditions) and thirdly, combining photodynamic compounds with super-pulsed, biofeedback laser technology to attack specifically targeted cancers, bacterium, viruses and fat cells.

The overriding competitive advantage of the Theralase laser technology is based on its more effective, deeper sub-dermal penetration capabilities. The primary and critical economic advantage of Theralase equipment for healthcare practitioners is that its NHN rating qualifies its units for several multiples of medical insurance reimbursement than that accorded to the limited ILY units.

This website portrays comprehensive information about Theralase’s technology, management, advisory board, and board of directors. For further inquiries or to request an investor kit, please contact Theralase at 1-866-843-5273, our highly trained staff is always eager to help.

---

Theralase Inc. is a subsidiary of Theralase Technologies Inc. (TLT – TSX.V)

Share Information

Stock Exchanges	TSX Venture Exchange
Trading Symbols	TLT
Issued Common Shares	39,172,558
Fully Diluted	42,122,558

SEDAR Filings

• Company documents (English)
• Company documents (French)

Stock Quote

• For a current Stock Quote, please Click Here.

 

 

2010

Second Quarter 2010 Financial Results
First Quarter 2010 Financial Results

---

2009

2009 Consolidated Financial Statements
2009 Management's Discussion & Analysis
Third Quarter 2009 Financial Results
Second Quarter 2009 Financial Results
First Quarter 2009 Financial Results

---

2008

2008 Consolidated Financial Statements
2008 Management's Discussion & Analysis
3rd Quarter Fiscal 2008
2nd Quarter Fiscal 2008
1st Quarter Fiscal 2008

---

2007

2007 Year End Report

2010

August 31		Theralase Laser Technologies Announces Q2 Financials
August 9		Theralase Welcomes Renowned Veterinarian to Medical & Scientific Advisory Board
June 8		Theralase Starts Small Animal Cancer Therapy Trials
May 31		Theralase Laser Technologies Announces Q1 Financials
April 29		Theralase Balances Research Breakthroughs with Fiscal Responsibility
January 5		Theralase Technologies Research Successfully Destroys Breast Cancer Cells

 

---

2009

December 14		Appointment of New Marketing Consultants
December 2		Theralase Continues To Grow: Q309 Financials
November 30		Theralase Closes Oversubscribed Equity Financing
October 19		Equity Financing Extended
September 30		Theralase Pursues Equity Financing
August 25		Theralase Posts Q2'2009 Increase in Revenue
May 29		Theralase Posts 42% Q1 Increase in Revenue
April 30		104% Q4 increase & 39% overall increase in sales
March 31		Theralase Advances On The Quest For Cancer Cure
March 17		Recognized by American Society of Laser Medicine

---

2008

November 27		Summary of Q3 2008 Results
November 18		Change to Board of Directors
October 7		Breakthrough Scientific Research
October 6		Proprietary Light System for Cancer Therapy
August 25		Theralase Increases Sales 40% in Q2
July 28		Theralase Appoints Corporate Business Development Officer
June 26		Changes To The Board
June 25		Changes to Board of Directors
May 30		2008 First Quarter Results
April 30		4th Quarter and Year-End Results
April 8		PDT Light-Based Systems
February 12		Positive Results in the Destruction of Cancer

---

2007

November 28		Summary of Q3 2007 Results
October 4		Stock Options Granted to VP Sales
September 12		Hired Leading IR Firm
August 22		Six Month Operating Results
August 16		Closed Private Placement
July 23		Advances Research on Cancer Treatment
July 16		Extends Closing of Equity Financing
July 3		Extends Closing of Equity Financing
June 4		Commences Equity Financing
May 16		1st Quarter Results
April 30		Financial Results Fiscal 2006
March 6		New Technology for Healing Tissue